A Phase Ib/II Multicenter Open-label Study of Bemcentinib (BGB324) in Patients With AML or MDS
- Status
- COMPLETED
- Phase
- PHASE1/PHASE2
Clinical Trials Related to Cytarabine
Related studies linked through entity extraction aliases.
CPI-613, Cytarabine, and Mitoxantrone Hydrochloride in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia or Granulocytic Sarcoma
- Status
- COMPLETED
- Phase
- PHASE1
Anti-CD20 Radioimmunotherapy Before Chemotherapy and Stem Cell Transplant in Treating Patients With High-Risk B-Cell Malignancies
- Status
- TERMINATED
- Phase
- PHASE1
Combination Chemotherapy, Rituximab, and Ixazomib Citrate in Treating Patients With Non-Hodgkin Lymphoma
- Status
- UNKNOWN
- Phase
- PHASE1/PHASE2
6,8-Bis(Benzylthio)Octanoic Acid, Cytarabine, and Daunorubicin Hydrochloride in Treating Older Patients With Newly Diagnosed Acute Myeloid Leukemia
- Status
- WITHDRAWN
- Phase
- PHASE1/PHASE2
Study of Idarubicin, Cytarabine, and Nivolumab in Patients With High-Risk Myelodysplastic Syndrome (MDS) and Acute Myeloid Leukemia (AML)
- Status
- COMPLETED
- Phase
- PHASE1/PHASE2
Ibrutinib Before and After Stem Cell Transplant in Treating Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE3
Allogeneic Hematopoietic Stem Cell Transplantation (AlloSCT) Initial Salvage Therapy for Induction Failure Acute Myeloid Leukemia (AML)
- Status
- COMPLETED
- Phase
- PHASE2
AML-02: Omacetaxine With Standard-of-Care Induction With Cytarabine & Idarubicin in Newly-Diagnosed AML Patients
- Status
- TERMINATED
- Phase
- PHASE1/PHASE2
Microtransplantation to Treat Refractory or Relapsed Hematologic Malignancies in Younger Patients
- Status
- TERMINATED
- Phase
- PHASE2
Treatment of Older Adult Acute Myeloid Leukemia Patients Aged 55 to 65 Years
- Status
- UNKNOWN
- Phase
- NA
Ibrutinib, Rituximab, and Consolidation Chemotherapy in Treating Young Patients With Newly Diagnosed Mantle Cell Lymphoma
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
Ruxolitinib Phosphate or Dasatinib With Chemotherapy in Treating Patients With Relapsed or Refractory Philadelphia Chromosome-Like Acute Lymphoblastic Leukemia
- Status
- TERMINATED
- Phase
- PHASE2
Bortezomib and Vorinostat in Younger Patients With Refractory or Relapsed MLL Rearranged Hematologic Malignancies
- Status
- TERMINATED
- Phase
- PHASE2
Augmented Berlin-Frankfurt-Munster Therapy Plus Ofatumumab for Young Adults With Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma
- Status
- TERMINATED
- Phase
- PHASE2
Study of CLAG + Selinexor in Relapsed or Refractory Acute Myeloid Leukemia
- Status
- COMPLETED
- Phase
- PHASE1/PHASE2
The Effect of Deferasirox on Response Rate of Acute Leukemia Patients Not Treated by Standard Chemotherapy Regimens
- Status
- UNKNOWN
- Phase
- PHASE1
Epigenetic Reprogramming in Relapse AML
- Status
- TERMINATED
- Phase
- PHASE1
A Study of Selinexor in Combination With Daunorubicin and Cytarabine for Untreated AML
- Status
- COMPLETED
- Phase
- PHASE1
Study of Crenolanib Combined With Chemotherapy in FLT3-mutated Acute Myeloid Leukemia Patients
- Status
- COMPLETED
- Phase
- PHASE1/PHASE2